European Urology Oncology

Slides:

Advertisements

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advertisements

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

Volume 71, Issue 2, Pages (February 2017)

Volume 155, Issue 3, Pages (March 1996)

European Urology Focus

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

European Urology Focus

Volume 65, Issue 4, Pages (April 2014)

European Urology Oncology

European Urology Oncology

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 4, Pages (April 2013)

European Urology Oncology

Volume 73, Issue 2, Pages (February 2018)

Volume 61, Issue 4, Pages (April 2012)

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

Volume 69, Issue 4, Pages (April 2016)

Volume 64, Issue 3, Pages (September 2013)

European Urology Oncology

Volume 148, Issue 1, Pages (January 2018)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 65, Issue 6, Pages (June 2014)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 4, Pages (October 2013)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Volume 62, Issue 3, Pages (September 2012)

Volume 71, Issue 2, Pages (February 2017)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Role of Checkpoint Inhibition in Localized Bladder Cancer

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

European Urology Oncology

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder Devin N. Patel, Michael Luu, Zachary.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

European Urology Oncology

Axel Heidenreich European Urology Supplements

Volume 152, Issue 1, Pages (January 2019)

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Volume 52, Issue 4, Pages (October 2007)

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

European Urology Oncology

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

European Urology Oncology

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Penile and Testicular Cancer: What's New in 2006?

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Rashed Ghandour, Nirmish Singla, Yair Lotan Trends in Cancer

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

European Urology Oncology

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Maximilian Burger, Ashish M. Kamat, David McConkey

Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

European Urology Oncology Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers Nieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, Evan Y. Yu, Ajjai S. Alva, Simon J. Crabb, Thomas Powles, Jonathan E. Rosenberg, Jack Baniel, Ulka N. Vaishampayan, Dominik R. Berthold, Sylvain Ladoire, Syed A. Hussain, Matthew I. Milowsky, Neeraj Agarwal, Andrea Necchi, Sumanta K. Pal, Cora N. Sternberg, Joaquim Bellmunt, Matthew D. Galsky, Lauren C. Harshman European Urology Oncology DOI: 10.1016/j.euo.2018.12.013 Copyright © 2019 Terms and Conditions

Fig. 1 Most frequently administered chemotherapeutic regimens in the neoadjuvant setting with the corresponding adjuvant therapy. Each line represents one patient's pathway. Carbo=carboplatin; ddMVAC=dose-dense methotrexate-vinblastine-adriamycin-cisplatin; GC=gemcitabine-cisplatin; MVAC=methotrexate-vinblastine-adriamycin-cisplatin. European Urology Oncology DOI: (10.1016/j.euo.2018.12.013) Copyright © 2019 Terms and Conditions

Fig. 2 Time to relapse (TTR) in patients with adverse residual disease (ypT3–4 and/or ypN+) despite neoadjuvant chemotherapy based on adjuvant chemotherapy use. (A) Patients with ypT3–4 and/or ypN+ residual disease. (B) Patients with ypT4b and/or ypN+ residual disease. Kaplan-Meier curves represent crude survival estimates. AC=adjuvant chemotherapy; NAC=neoadjuvant chemotherapy; Obs=observation. aMultivariable analyses were adjusted for pathological stage (stage III and stage IV disease), type of NAC (cisplatin based, carboplatin based, and other regimens), and age. European Urology Oncology DOI: (10.1016/j.euo.2018.12.013) Copyright © 2019 Terms and Conditions

Fig. 3 Overall survival (OS) by use of adjuvant chemotherapy. Kaplan-Meier curves represent crude survival estimates. AC=adjuvant chemotherapy; NAC=neoadjuvant chemotherapy; Obs=observation. aMultivariable analyses were adjusted for pathological stage (stage III and stage IV disease), type of NAC (cisplatin-based and carboplatin-based and other regimens), and age. European Urology Oncology DOI: (10.1016/j.euo.2018.12.013) Copyright © 2019 Terms and Conditions